• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nyxoah SA

    4/6/23 4:42:51 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care
    Get the next $NYXH alert in real time by email
    SC 13G 1 d441844dsc13g.htm SC 13G SC 13G
    CUSIP No. B6S7WD106    13G    Page 1 of 5

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    Nyxoah SA

    (Name of Issuer)

    Ordinary Shares

    (Title of Class of Securities)

    B6S7WD106

    (CUSIP Number)

    March 30, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. B6S7WD106    13G    Page 2 of 5

     

      1.    

      Names of Reporting Persons

     

      ResMed Inc.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      1,499,756

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

      1,499,756

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,499,756

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.38% (1)

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    (1)

    Based on an aggregate amount of 27,393,823 ordinary shares (“Ordinary Shares”) of Nyxoah SA (the “Issuer”), of which 25,846,279 Ordinary Shares stated to be outstanding in the Issuer’s Form 20-F furnished to the Securities and Exchange Commission (“SEC”) on March 22, 2023 and an additional 2,047,544 Ordinary Shares issued pursuant to a private placement financing on March [30], 2023.


    CUSIP No. B6S7WD106    13G    Page 3 of 5

     

    Item 1.

     

      (a)

    Name of issuer

    Nyxoah SA (the “Issuer”).

     

      (b)

    Address of issuer’s principal executive offices

    Rue Edouard Belin 12

    1435 Mont-Saint-Guibert, Belgium

     

    Item 2.

     

      (a)

    Name of person filing

    ResMed Inc. (the “Reporting Person”).

     

      (b)

    Address or principal business office or, if none, residence

    9001 Spectrum Center Blvd.

    San Diego, CA 92123

     

      (c)

    Citizenship

    Delaware

     

      (d)

    Title of class of securities

    Ordinary Shares

     

      (e)

    CUSIP No.

    B6S7WD106

     

    Item 3.

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

    Not applicable

     

    Item 4.

    Ownership

    The responses to Items 5-11 of the cover page of this Schedule 13G are incorporated herein by reference.

     

    (a)

    Amount beneficially owned: 1,499,756 Ordinary Shares

     

    (b)

    Percent of class: 5.38%

     

    (c)

    Number of shares as to which the person has:

     

    (i)

    Sole power to vote or to direct the vote: 1,499,756

     

    (ii)

    Shared power to vote or to direct the vote: 0

     

    (iii)

    Sole power to dispose of or to direct the disposition of: 1,499,756

     

    (iv)

    Shared power to dispose of or to direct the disposition of: 0

     

    Item 5.

    Ownership of 5 Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.


    CUSIP No. B6S7WD106    13G    Page 4 of 5

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. B6S7WD106    13G    Page 5 of 5

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: April 6, 2023

     

    RESMED INC.

    By:

     

    /s/ Brett Sandercock

    Name: Brett Sandercock

    Its: Chief financial officer

    Get the next $NYXH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NYXH

    DatePrice TargetRatingAnalyst
    7/31/2023Buy
    H.C. Wainwright
    7/19/2023Neutral
    Robert W. Baird
    4/21/2022$30.00Outperform
    Oppenheimer
    4/6/2022$21.00Peer Perform
    Wolfe Research
    12/21/2021$47.00Overweight
    Cantor Fitzgerald
    7/28/2021$43.00Overweight
    Cantor Fitzgerald
    7/28/2021$40.00Overweight
    Piper Sandler
    7/27/2021$43.00Buy
    Stifel
    More analyst ratings